Although sufficient case data to characterize the specific imaging features of SMARCA4-deficient undifferentiated RCC are currently lacking, their high metastatic potential and metabolic activity suggest that the integration of CT/MRI with PET/CT should be incorporated into diagnostic workflows and clinical staging. This evidence concerns the gene SMARCA4 and renal cell carcinoma.